136 related articles for article (PubMed ID: 7961108)
1. Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion.
Tamura T; Sasaki Y; Eguchi K; Shinkai T; Ohe Y; Nishio M; Kunikane H; Arioka H; Karato A; Omatsu H
Jpn J Cancer Res; 1994 Oct; 85(10):1057-62. PubMed ID: 7961108
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
Tamura T; Sasaki Y; Nishiwaki Y; Saijo N
Jpn J Cancer Res; 1995 Dec; 86(12):1203-9. PubMed ID: 8636011
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
[TBL] [Abstract][Full Text] [Related]
4. [Phase I study of paclitaxel].
Horikoshi N; Inoue K; Aiba K; Mukaiyama T; Ogihara A; Sumida T; Akatsuka Y; Besho A; Inamoto Y; Uchida T
Gan To Kagaku Ryoho; 1994 Oct; 21(14):2407-14. PubMed ID: 7944484
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
J Clin Oncol; 1994 Feb; 12(2):241-8. PubMed ID: 7509380
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.
Maier-Lenz H; Hauns B; Haering B; Koetting J; Mross K; Unger C; Bauknecht T; du Bois A; Meerpohl HG; Hollaender N; Diergarten K
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-16-S19-19. PubMed ID: 9427259
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
Hainsworth JD; Raefsky EL; Greco FA
Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of paclitaxel administered by ten-day continuous infusion.
Shade RJ; Pisters KM; Huber MH; Fossella F; Perez-Soler R; Shin DM; Kurie J; Glisson B; Lippman S; Lee JS
Invest New Drugs; 1998-1999; 16(3):237-43. PubMed ID: 10360603
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Hainsworth JD; Greco FA
Cancer; 1994 Aug; 74(4):1377-82. PubMed ID: 7914470
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
Wilson WH; Berg SL; Bryant G; Wittes RE; Bates S; Fojo A; Steinberg SM; Goldspiel BR; Herdt J; O'Shaughnessy J
J Clin Oncol; 1994 Aug; 12(8):1621-9. PubMed ID: 7913721
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Rowinsky EK; Smith L; Wang YM; Chaturvedi P; Villalona M; Campbell E; Aylesworth C; Eckhardt SG; Hammond L; Kraynak M; Drengler R; Stephenson J; Harding MW; Von Hoff DD
J Clin Oncol; 1998 Sep; 16(9):2964-76. PubMed ID: 9738565
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.
Sessa C; Cuvier C; Caldiera S; Bauer J; Van Den Bosch S; Monnerat C; Semiond D; Pérard D; Lebecq A; Besenval M; Marty M
Ann Oncol; 2002 Jul; 13(7):1140-50. PubMed ID: 12176795
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.
Doz F; Gentet JC; Pein F; Frappaz D; Chastagner P; Moretti S; Vassal G; Arditti J; Tellingen OV; Iliadis A; Catalin J
Br J Cancer; 2001 Mar; 84(5):604-10. PubMed ID: 11237379
[TBL] [Abstract][Full Text] [Related]
18. A feasibility study of 1-h paclitaxel infusion in patients with solid tumors.
Tsavaris N; Polyzos A; Kosmas C; Giannikos L; Gogas J
Cancer Chemother Pharmacol; 1997; 40(4):353-7. PubMed ID: 9225955
[TBL] [Abstract][Full Text] [Related]
19. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
Löffler TM; Freund W; Lipke J; Hausamen TU
Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.
Hurwitz CA; Relling MV; Weitman SD; Ravindranath Y; Vietti TJ; Strother DR; Ragab AH; Pratt CB
J Clin Oncol; 1993 Dec; 11(12):2324-9. PubMed ID: 7902425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]